Skip to main content

Imerys No Longer A Defendant In Upcoming Talc Trial

Imerys No Longer A Defendant In Upcoming Talc Trial

Imerys No Longer A Defendant In Upcoming Talc Trial

Introduction

On Thursday, February 14, Alameda County Superior Court Judge Brad Seligman announced that Imerys Talc America Inc. was no longer a defendant in a trial involving claims filed on behalf of a dying woman suffering from cancer allegedly due to Johnson & Johnson's talcum powder. The jurors were instructed not to contemplate much on why the talc supplier was dropped from the trial.

Imerys Talc America Inc. and its affiliates, Imerys Talc Vermont and Imerys Talc Canada filed for Chapter 11 bankruptcy on Wednesday, February 13 in Delaware, amidst multi-million dollar lawsuits that allege that asbestos exposure from J&J's talcum powder cause ovarian cancer and mesothelioma. Imerys stated that it has been named as a defendant in more than 14,650 individual claims and is currently $100 million in debt resulting from fighting those cases. Until Thursday, Imerys was part of the trial involving a plaintiff's claims that J&J and multiple mining companies, owned by Imerys, were aware of the asbestos hazards for decades and yet failed to adequately warn the consumers. The trial is expected to go before the jury early in March.

Other defendants targeted in the talcum powder litigation are Colgate-Palmolive Co., Whittaker, Clark & Daniels, and Vanderbilt Minerals.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!